StemOneTM/Stempeucel®: CDSCO Approved, Adult Human Bone Marrow-Derived, Cultured, Pooled, Allogenic Mesenchymal Stem Cells for Knee Osteoarthritis

doi:10.3390/biomedicines11112894

Editorial

. 2023 Oct 26;11(11):2894.

doi: 10.3390/biomedicines11112894.

StemOne^TM/Stempeucel^®: CDSCO Approved, Adult Human Bone Marrow-Derived, Cultured, Pooled, Allogenic Mesenchymal Stem Cells for Knee Osteoarthritis

Ashim Gupta^{1

2}

Affiliations

PMID: 38001895
PMCID: PMC10669254
DOI: 10.3390/biomedicines11112894

Editorial

StemOne^TM/Stempeucel^®: CDSCO Approved, Adult Human Bone Marrow-Derived, Cultured, Pooled, Allogenic Mesenchymal Stem Cells for Knee Osteoarthritis

Ashim Gupta. Biomedicines. 2023.

. 2023 Oct 26;11(11):2894.

doi: 10.3390/biomedicines11112894.

Author

Ashim Gupta^{1

2}

Affiliations

¹ Regenerative Orthopaedics, Noida 201301, India.
² Future Biologics, Lawrenceville, GA 30043, USA.

PMID: 38001895
PMCID: PMC10669254
DOI: 10.3390/biomedicines11112894

Abstract

The knee, the most likely joint to present osteoarthritis (OA), is accountable for approximately 80% of the global burden of the OA [...].

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Cited by

Autologous Growth Factor-Rich Concentrate (GFC) Injection in Non-union of Fractures: A Quasi-experimental Study.
Jain K, Jeyaraman M, Jeyaraman N, Gupta A. Jain K, et al. Indian J Orthop. 2024 Oct 5;58(12):1833-1843. doi: 10.1007/s43465-024-01278-1. eCollection 2024 Dec. Indian J Orthop. 2024. PMID: 39664350

References

1. Gupta A., Sharma S.P., Potty A.G. Combination of Platelet-Rich Plasma and Hyaluronic Acid vs. Platelet-Rich Plasma Alone for Treatment of Knee Osteoarthritis. Biomedicines. 2023;11:2759. doi: 10.3390/biomedicines11102759. - DOI - PMC - PubMed
1. Gupta A. Platelet-Rich Plasma One Week Prior to Hyaluronic Acid vs. Platelet-Rich Plasma Alone for the Treatment of Knee Osteoarthritis. Biomedicines. 2022;10:2805. doi: 10.3390/biomedicines10112805. - DOI - PMC - PubMed
1. Gupta A., Jeyaraman M., Maffulli N. Common Medications Which Should Be Stopped Prior to Platelet-Rich Plasma Injection. Biomedicines. 2022;10:2134. doi: 10.3390/biomedicines10092134. - DOI - PMC - PubMed
1. Gupta A. Allogenic Amniotic Tissue for Treatment of Knee and Hip Osteoarthritis. Pharmaceuticals. 2022;15:404. doi: 10.3390/ph15040404. - DOI - PMC - PubMed
1. Sokolove J., Lepus C.M. Role of inflammation in the pathogenesis of osteoarthritis: Latest findings and interpretations. Ther. Adv. Musculoskelet. Dis. 2013;5:77–94. doi: 10.1177/1759720X12467868. - DOI - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

[1] Gupta A., Sharma S.P., Potty A.G. Combination of Platelet-Rich Plasma and Hyaluronic Acid vs. Platelet-Rich Plasma Alone for Treatment of Knee Osteoarthritis. Biomedicines. 2023;11:2759. doi: 10.3390/biomedicines11102759. - DOI - PMC - PubMed

[2] Gupta A., Sharma S.P., Potty A.G. Combination of Platelet-Rich Plasma and Hyaluronic Acid vs. Platelet-Rich Plasma Alone for Treatment of Knee Osteoarthritis. Biomedicines. 2023;11:2759. doi: 10.3390/biomedicines11102759. - DOI - PMC - PubMed

[3] Gupta A. Platelet-Rich Plasma One Week Prior to Hyaluronic Acid vs. Platelet-Rich Plasma Alone for the Treatment of Knee Osteoarthritis. Biomedicines. 2022;10:2805. doi: 10.3390/biomedicines10112805. - DOI - PMC - PubMed

[4] Gupta A. Platelet-Rich Plasma One Week Prior to Hyaluronic Acid vs. Platelet-Rich Plasma Alone for the Treatment of Knee Osteoarthritis. Biomedicines. 2022;10:2805. doi: 10.3390/biomedicines10112805. - DOI - PMC - PubMed

[5] Gupta A., Jeyaraman M., Maffulli N. Common Medications Which Should Be Stopped Prior to Platelet-Rich Plasma Injection. Biomedicines. 2022;10:2134. doi: 10.3390/biomedicines10092134. - DOI - PMC - PubMed

[6] Gupta A., Jeyaraman M., Maffulli N. Common Medications Which Should Be Stopped Prior to Platelet-Rich Plasma Injection. Biomedicines. 2022;10:2134. doi: 10.3390/biomedicines10092134. - DOI - PMC - PubMed

[7] Gupta A. Allogenic Amniotic Tissue for Treatment of Knee and Hip Osteoarthritis. Pharmaceuticals. 2022;15:404. doi: 10.3390/ph15040404. - DOI - PMC - PubMed

[8] Gupta A. Allogenic Amniotic Tissue for Treatment of Knee and Hip Osteoarthritis. Pharmaceuticals. 2022;15:404. doi: 10.3390/ph15040404. - DOI - PMC - PubMed

[9] Sokolove J., Lepus C.M. Role of inflammation in the pathogenesis of osteoarthritis: Latest findings and interpretations. Ther. Adv. Musculoskelet. Dis. 2013;5:77–94. doi: 10.1177/1759720X12467868. - DOI - PMC - PubMed

[10] Sokolove J., Lepus C.M. Role of inflammation in the pathogenesis of osteoarthritis: Latest findings and interpretations. Ther. Adv. Musculoskelet. Dis. 2013;5:77–94. doi: 10.1177/1759720X12467868. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

StemOne^TM/Stempeucel^®: CDSCO Approved, Adult Human Bone Marrow-Derived, Cultured, Pooled, Allogenic Mesenchymal Stem Cells for Knee Osteoarthritis

Affiliations

StemOne^TM/Stempeucel^®: CDSCO Approved, Adult Human Bone Marrow-Derived, Cultured, Pooled, Allogenic Mesenchymal Stem Cells for Knee Osteoarthritis

Author

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

Related information

LinkOut - more resources

Full Text Sources